Association of interleukin-enhanced factor 2 (ILF2) expression with prognosis and clinico-genomic features in breast cancer (BC). ASCO,  Abst: 1030 Poster: 408, 6/2022.

Matias Bustos; Dave S.B. Hoon; See all authors in notes

Association of interleukin-enhanced factor 2 (ILF2) expression with prognosis and clinico-genomic features in breast cancer (BC). ASCO, Abst: 1030 Poster: 408, 6/2022.

Matias Bustos, Dave S.B. Hoon, See all authors in notes

Research output: Contribution to conference › Abstract

Original language	American English
State	Published - 2022

Cite this

@conference{673ef5fc4b5c479db6e42d3a3598776e,

title = "Association of interleukin-enhanced factor 2 (ILF2) expression with prognosis and clinico-genomic features in breast cancer (BC). ASCO, Abst: 1030 Poster: 408, 6/2022.",

author = "Matias Bustos and Hoon, {Dave S.B.} and {See all authors in notes}",

note = "287. Bustos M, Yin J, Brodskiy P, Kang I, Graff SL, Sammons S, Dawar R, Spetzler D, Hoon DSB. ",

year = "2022",

language = "American English",

}

TY - CONF

T1 - Association of interleukin-enhanced factor 2 (ILF2) expression with prognosis and clinico-genomic features in breast cancer (BC). ASCO, Abst: 1030 Poster: 408, 6/2022.

AU - Bustos, Matias

AU - Hoon, Dave S.B.

AU - See all authors in notes,

N1 - 287. Bustos M, Yin J, Brodskiy P, Kang I, Graff SL, Sammons S, Dawar R, Spetzler D, Hoon DSB.

PY - 2022

Y1 - 2022

M3 - Abstract

ER -